Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms

G. Tancini, S. Bar Ni, R. Rescaldani, G. Fiorelli, S. Viviani, P. Lissoni

Research output: Contribution to journalArticle

Abstract

Neoplastic diseases affect the immunity in cancer patients. The immune alterations in human neoplasms, however, need to be further defined. The present study was carried out to analyze T lymphocyte subsets in patients with solid tumors. The study included 93 patients suffering from early or metastatic solid neoplasms. T helper and T suppressor subsets were measured on venous blood samples by using flow cytometry and monoclonal antibodies. As controls, 58 healthy subjects were included in the study. The T mean helper/ suppressor ratio (CD4/CD8) was significantly lower in metastatic cancer patients with respect to that observed either in controls or in patients without metastases. A low CD4/CD8 ratio was seen in 25 of 93 cancer patients (26.9%), 8 of whom had no metastases, while the other 17 showed a metastatic disease. Within the nonmetastatic group, the decline in the CD4/CD8 ratio was due to increases in the T suppressor subset alone in 7. On the contrary, the percentage of cases with decreased T helper subset was significantly higher in metastatic than in the nonmetastatic patients. The results of this study suggest that the decrease in the CD4/CD8 ratio mainly depends on an increase in T suppressor cells in patients without metastases, whereas it is due to a decrease in the T helper subset in most patients with metastatic diseases.

Original languageEnglish
Pages (from-to)381-384
Number of pages4
JournalOncology
Volume47
Issue number5
DOIs
Publication statusPublished - 1990

Fingerprint

Lymphocyte Subsets
CD4-CD8 Ratio
Neoplasms
Neoplasm Metastasis
T-Lymphocyte Subsets
Immunity
Healthy Volunteers
Flow Cytometry
Monoclonal Antibodies

Keywords

  • CD4/CD8 ratio
  • T helper lymphocyte subsets
  • T suppressor lymphocyte subsets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tancini, G., Bar Ni, S., Rescaldani, R., Fiorelli, G., Viviani, S., & Lissoni, P. (1990). Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology, 47(5), 381-384. https://doi.org/10.1159/000226852

Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. / Tancini, G.; Bar Ni, S.; Rescaldani, R.; Fiorelli, G.; Viviani, S.; Lissoni, P.

In: Oncology, Vol. 47, No. 5, 1990, p. 381-384.

Research output: Contribution to journalArticle

Tancini, G, Bar Ni, S, Rescaldani, R, Fiorelli, G, Viviani, S & Lissoni, P 1990, 'Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms', Oncology, vol. 47, no. 5, pp. 381-384. https://doi.org/10.1159/000226852
Tancini, G. ; Bar Ni, S. ; Rescaldani, R. ; Fiorelli, G. ; Viviani, S. ; Lissoni, P. / Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. In: Oncology. 1990 ; Vol. 47, No. 5. pp. 381-384.
@article{d4e96061619945479ad8381e53d48c1a,
title = "Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms",
abstract = "Neoplastic diseases affect the immunity in cancer patients. The immune alterations in human neoplasms, however, need to be further defined. The present study was carried out to analyze T lymphocyte subsets in patients with solid tumors. The study included 93 patients suffering from early or metastatic solid neoplasms. T helper and T suppressor subsets were measured on venous blood samples by using flow cytometry and monoclonal antibodies. As controls, 58 healthy subjects were included in the study. The T mean helper/ suppressor ratio (CD4/CD8) was significantly lower in metastatic cancer patients with respect to that observed either in controls or in patients without metastases. A low CD4/CD8 ratio was seen in 25 of 93 cancer patients (26.9{\%}), 8 of whom had no metastases, while the other 17 showed a metastatic disease. Within the nonmetastatic group, the decline in the CD4/CD8 ratio was due to increases in the T suppressor subset alone in 7. On the contrary, the percentage of cases with decreased T helper subset was significantly higher in metastatic than in the nonmetastatic patients. The results of this study suggest that the decrease in the CD4/CD8 ratio mainly depends on an increase in T suppressor cells in patients without metastases, whereas it is due to a decrease in the T helper subset in most patients with metastatic diseases.",
keywords = "CD4/CD8 ratio, T helper lymphocyte subsets, T suppressor lymphocyte subsets",
author = "G. Tancini and {Bar Ni}, S. and R. Rescaldani and G. Fiorelli and S. Viviani and P. Lissoni",
year = "1990",
doi = "10.1159/000226852",
language = "English",
volume = "47",
pages = "381--384",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Analysis of t helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms

AU - Tancini, G.

AU - Bar Ni, S.

AU - Rescaldani, R.

AU - Fiorelli, G.

AU - Viviani, S.

AU - Lissoni, P.

PY - 1990

Y1 - 1990

N2 - Neoplastic diseases affect the immunity in cancer patients. The immune alterations in human neoplasms, however, need to be further defined. The present study was carried out to analyze T lymphocyte subsets in patients with solid tumors. The study included 93 patients suffering from early or metastatic solid neoplasms. T helper and T suppressor subsets were measured on venous blood samples by using flow cytometry and monoclonal antibodies. As controls, 58 healthy subjects were included in the study. The T mean helper/ suppressor ratio (CD4/CD8) was significantly lower in metastatic cancer patients with respect to that observed either in controls or in patients without metastases. A low CD4/CD8 ratio was seen in 25 of 93 cancer patients (26.9%), 8 of whom had no metastases, while the other 17 showed a metastatic disease. Within the nonmetastatic group, the decline in the CD4/CD8 ratio was due to increases in the T suppressor subset alone in 7. On the contrary, the percentage of cases with decreased T helper subset was significantly higher in metastatic than in the nonmetastatic patients. The results of this study suggest that the decrease in the CD4/CD8 ratio mainly depends on an increase in T suppressor cells in patients without metastases, whereas it is due to a decrease in the T helper subset in most patients with metastatic diseases.

AB - Neoplastic diseases affect the immunity in cancer patients. The immune alterations in human neoplasms, however, need to be further defined. The present study was carried out to analyze T lymphocyte subsets in patients with solid tumors. The study included 93 patients suffering from early or metastatic solid neoplasms. T helper and T suppressor subsets were measured on venous blood samples by using flow cytometry and monoclonal antibodies. As controls, 58 healthy subjects were included in the study. The T mean helper/ suppressor ratio (CD4/CD8) was significantly lower in metastatic cancer patients with respect to that observed either in controls or in patients without metastases. A low CD4/CD8 ratio was seen in 25 of 93 cancer patients (26.9%), 8 of whom had no metastases, while the other 17 showed a metastatic disease. Within the nonmetastatic group, the decline in the CD4/CD8 ratio was due to increases in the T suppressor subset alone in 7. On the contrary, the percentage of cases with decreased T helper subset was significantly higher in metastatic than in the nonmetastatic patients. The results of this study suggest that the decrease in the CD4/CD8 ratio mainly depends on an increase in T suppressor cells in patients without metastases, whereas it is due to a decrease in the T helper subset in most patients with metastatic diseases.

KW - CD4/CD8 ratio

KW - T helper lymphocyte subsets

KW - T suppressor lymphocyte subsets

UR - http://www.scopus.com/inward/record.url?scp=0025082092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025082092&partnerID=8YFLogxK

U2 - 10.1159/000226852

DO - 10.1159/000226852

M3 - Article

C2 - 2145536

AN - SCOPUS:0025082092

VL - 47

SP - 381

EP - 384

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -